Catalyst
Slingshot members are tracking this event:
Bayer (BAYRY) Announces Regulatory Submission of Regorafenib in Second-Line Treatment of Liver Cancer in U.S, Europe, and Japan
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BAYRY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 07, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Regulatory Submission, Regorafenib, Second-line Treatment, Liver Cancer, U.s, Japan, Europe, Fda, Ema, Phase 3, Resorce
